Abstract
We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.
Original language | English (US) |
---|---|
Pages (from-to) | 1229-1230 |
Number of pages | 2 |
Journal | Cancer treatment reports |
Volume | 66 |
Issue number | 5 |
State | Published - 1982 |
ASJC Scopus subject areas
- Oncology
- Cancer Research